

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

The committee considered the impact of the potential equality issues on the recommendations about cabozantinib, and whether it would be harder for particular groups to access treatment.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

Expert statement stated that liver disease and liver cancer disproportionately affect the poorest in society, and many people with liver cancer come from disadvantaged backgrounds. The committee acknowledged the potential equality issue. Differences in prevalence and patient population cannot usually be resolved in a technology appraisal.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

The committee was concerned that fewer people from ethnic minority backgrounds may be able to have a liver transplant because of the lack of suitable donors, potentially increasing the likelihood that they will need systemic treatment. However, the experts explained that this was less of an issue in HCC than some other diseases.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes. Section 3.13

Approved by Associate Director (name): Ross Dent

Date: 20/10/2022